For the last 25 years, research in Alzheimer’s disease has focused on amyloid as the key driver of disease pathogenesis. However, the recent failure of several Phase III clinical trials targeting amyloid has reinforced the need to critically evaluate these trials and consider different approaches. There is burgeoning interest in identifying alternative drug targets: over half of ongoing preclinical research in Alzheimer’s disease now focuses on neuro-inflammation, bioenergetics, epigenetics, protein homeostasis and other alternative pathways.

This conference will consider the landscape of Alzheimer’s disease research including the current state of the amyloid hypothesis, emerging disease mechanisms, and strategies to develop novel therapeutic approaches.